^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SYSA1901 (pertuzumab biosimilar)

    i
    Other names: SYSA1901
    Associations

    News

    Trials
    Company:
    CSPC Pharma
    Drug class:
    HER2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer (clinicaltrials.gov)
    P3, N=560, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • PGR negative
    |
    docetaxel • Perjeta (pertuzumab) • SYSA1901 (pertuzumab biosimilar)